insights_auto
ΠΠ°ΡΠΎ AXGN Π±Π΅Π»Π΅ΠΆΠΈ ΡΠΏΠ°Π΄ 5,06%?
ΠΠΎ-ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎ ΡΠ°Π·Π³Π»Π΅ΠΆΠ΄Π°Π½Π΅chevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
48,75Β Ρ.Π΄.
arrow_downward
-5,06%(-2,60) 1Β Π΄.
48,55Β Ρ.Π΄.
arrow_downward
-0,41% (-0,20)todayΠΡΠ΅Π΄ΠΈ ΠΎΡΠ²Π°ΡΡΠ½Π΅ΡΠΎ Π½Π° Π±ΠΎΡΡΠ°ΡΠ°
ΠΠ°ΡΠ²ΠΎΡΠ΅Π½ΠΎ: 5.11, 16:00:01 Ρ. ΠΡΠΈΠ½ΡΠΈΡ-5 · USD
search
ΠΡΠΈΡΠΊΠΈ ΡΠΈΠΌΠ²ΠΎΠ»ΠΈ
| Π‘ΠΈΠΌΠ²ΠΎΠ» | Π¦Π΅Π½Π° | ΠΡΠΎΠΌΡΠ½Π° | % ΠΏΡΠΎΠΌΡΠ½Π° |
|---|
insights_autoΠΠ΅Π½Π΅ΡΠΈΡΠ° ΡΠ΅ Π²ΠΎΠ΄Π΅ΡΠ°ΡΠ° ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ° Π·Π° AXGNβ¦
ΠΡΠ²Π°ΡΡΠ½Π΅
51,62Β Ρ.Π΄.
ΠΠΈΡΠΎΠΊΠ°
51,85Β Ρ.Π΄.
ΠΠΈΡΠΊΠ°
47,57Β Ρ.Π΄.
ΠΠ°Π·Π°ΡΠ½Π° ΠΊΠ°ΠΏ.
2,91Β ΠΌΠ»ΡΠ΄.
Π‘Ρ. ΠΎΠ±Π΅ΠΌ
1,78Β ΠΌΠ»Π½.
ΠΠ±Π΅ΠΌ
375,00
ΠΠ°ΠΉ-Π²ΠΈΡΠΎΠΊΠ° ΡΠ΅Π½Π° Π·Π° 52 ΡΠ΅Π΄ΠΌ.
52,91Β Ρ.Π΄.
ΠΠ°ΠΉ-Π½ΠΈΡΠΊΠ° ΡΠ΅Π½Π° Π·Π° 52 ΡΠ΅Π΄ΠΌ.
23,00Β Ρ.Π΄.
EPS
-0,68Β Ρ.Π΄.
ΠΠ΅ΡΠ°-Π²Π΅ΡΡΠΈΡ
1,21
ΠΠΊΡΠΈΠΈ Π² ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅
59,73Β ΠΌΠ»Π½.
ΠΡΠΎΠΉ ΡΠ»ΡΠΆΠΈΡΠ΅Π»ΠΈ
622
ΠΡΠ²Π°ΡΡΠ½Π΅
51,62Β Ρ.Π΄.
ΠΠΈΡΠΎΠΊΠ°
51,85Β Ρ.Π΄.
ΠΠΈΡΠΊΠ°
47,57Β Ρ.Π΄.
ΠΠ°Π·Π°ΡΠ½Π° ΠΊΠ°ΠΏ.
2,91Β ΠΌΠ»ΡΠ΄.
Π‘Ρ. ΠΎΠ±Π΅ΠΌ
1,78Β ΠΌΠ»Π½.
ΠΠ±Π΅ΠΌ
375,00
ΠΠ°ΠΉ-Π²ΠΈΡΠΎΠΊΠ° ΡΠ΅Π½Π° Π·Π° 52 ΡΠ΅Π΄ΠΌ.
52,91Β Ρ.Π΄.
ΠΠ°ΠΉ-Π½ΠΈΡΠΊΠ° ΡΠ΅Π½Π° Π·Π° 52 ΡΠ΅Π΄ΠΌ.
23,00Β Ρ.Π΄.
EPS
-0,68Β Ρ.Π΄.
ΠΠ΅ΡΠ°-Π²Π΅ΡΡΠΈΡ
1,21
ΠΠΊΡΠΈΠΈ Π² ΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΠ΅
59,73Β ΠΌΠ»Π½.
ΠΡΠΎΠΉ ΡΠ»ΡΠΆΠΈΡΠ΅Π»ΠΈ
622
ΠΠΎΠ²ΠΈΠ½Π°ΡΡΠΊΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΈ
ΠΡ ΠΈΠ·ΡΠΎΡΠ½ΠΈΡΠΈ Π² ΠΌΡΠ΅ΠΆΠ°ΡΠ° ΠΈ Π½ΠΎΠ²ΠΈΠ½Π°ΡΡΠΊΠΈ ΠΏΠ°ΡΡΠ½ΡΠΎΡΠΈ
Investor.bg
·
ΠΏΡΠ΅Π΄ΠΈ 12 ΡΠ°ΡΠ°
S&P 500 ΠΎΡΡΠ΅ΡΠ΅ Π½Π°ΠΉ-Π»ΠΎΡΠΎΡΠΎ ΡΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΡΠ½Π΅ ΠΎΡ Π°ΠΏΡΠΈΠ» 2025 Π³., Nasdaq Π½Π°Π²Π»Π΅Π·Π΅ Π² Π·ΠΎΠ½Π° Π½Π° ΠΊΠΎΡΠ΅ΠΊΡΠΈΡ
Investor.bg
·
ΠΏΡΠ΅Π΄ΠΈ 19 ΡΠ°ΡΠ°
Dow ΡΠ΅ ΠΏΠΎΠ²ΠΈΡΠ°Π²Π° Ρ ΠΎΡΠ΅ 300 ΠΏΡΠ½ΠΊΡΠ° Π½Π° ΡΠΎΠ½Π° Π½Π° ΡΠΈΠ»Π½ΠΈΡ ΠΏΠΎΠ΄Π΅ΠΌ ΡΠ»Π΅Π΄ ΠΌΠ΅ΠΆΠ΄ΠΈΠ½Π½ΠΈΡΠ΅ ΠΈΠ·Π±ΠΎΡΠΈ Π² Π‘ΠΠ©
Rock Hill Herald
·
ΠΏΡΠ΅Π΄ΠΈ 29 ΠΌΠΈΠ½ΡΡΠΈ
Nasdaq futures rise after steep AI selloff as chip stocks stabilize
The Motley Fool
·
ΠΏΡΠ΅Π΄ΠΈ 58 ΠΌΠΈΠ½ΡΡΠΈ
Yikes! The Stock Market Just Did Something It Has Never Done Before. History Is Clear About What Comes Next.
ΠΡΠΎΡΠΈΠ»
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
ΠΡΠΈΡΠΊΠΎ Π·Π° AxoGen, Inc Common Stock
ΠΠ»Π°Π²Π΅Π½ ΠΈΠ·ΠΏΡΠ»Π½ΠΈΡΠ΅Π»Π΅Π½ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ-
Π‘Π»ΡΠΆΠΈΡΠ΅Π»ΠΈ622
ΠΠ°ΡΠ° Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π²Π°Π½Π΅2002
Π¦Π΅Π½ΡΡΠ°Π»Π΅Π½ ΠΎΡΠΈΡAlachua, Π€Π»ΠΎΡΠΈΠ΄Π°, Π‘ΡΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈ ΡΠ°ΡΠΈ
ΠΡΠ°Π½ΡHealth Care
Industry-
Π£Π΅Π±ΡΠ°ΠΉΡaxogeninc.com